Authorized purpose: Adjunctive assignment of a BI-RADS 5th Edition breast-density category for interpreting-physician review of mammography.
Clinical role
Adjunctive post-processing breast-density categorization and reporting support; physician review and judgment remain required
Images and patients
Mammography/DBT · Breast tissue composition
Key limitation
Keep in mind: The device is adjunctive and not a diagnostic aid or replacement for physician review; decisions must not rely solely on its analysis. Use is labeled for compatible FFDM/DBT systems and female patients aged 35 or older.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adjunctive assignment of a BI-RADS 5th Edition breast-density category for interpreting-physician review of mammography.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast tissue composition Input: A single x-ray mammogram study with acceptable 2D image DICOM files from FFDM and/or 2D synthetic images, used with compatible FFDM and DBT systems; labeled patients are females aged 35 or older undergoing mammography.
Who uses it?Intended users: Interpreting physicians qualified to read mammography exams
What does the software produce?Output: One study-level breast-density category from A through D under BI-RADS 5th Edition guidelines, delivered as a DICOM Structured Report containing the case-level category and a DICOM Secondary Capture summary report viewable on a mammography workstation.
What is its most important limitation?Key limitation: The device is adjunctive and not a diagnostic aid or replacement for physician review; decisions must not rely solely on its analysis. Use is labeled for compatible FFDM/DBT systems and female patients aged 35 or older.
Clinical takeaway. Clinical role: Adjunctive assignment of a BI-RADS 5th Edition breast-density category for interpreting-physician review of mammography.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: software unit, integration, and system verification plus retrospective validation described as performed under prior submission K222275. Validation data came from clinical sites distinct from algorithm-development sites, with no training/test overlap stated in this packet; K243705 itself discloses no sample size or numeric sensitivity, specificity, AUC, or other clinical performance values.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adjunctive assignment of a BI-RADS 5th Edition breast-density category for interpreting-physician review of mammography.
A single x-ray mammogram study with acceptable 2D image DICOM files from FFDM and/or 2D synthetic images, used with compatible FFDM and DBT systems; labeled patients are females aged 35 or older undergoing mammography.
One study-level breast-density category from A through D under BI-RADS 5th Edition guidelines, delivered as a DICOM Structured Report containing the case-level category and a DICOM Secondary Capture summary report viewable on a mammography workstation.
The device is adjunctive and not a diagnostic aid or replacement for physician review; decisions must not rely solely on its analysis. Use is labeled for compatible FFDM/DBT systems and female patients aged 35 or older.
FDA packet: software unit, integration, and system verification plus retrospective validation described as performed under prior submission K222275. Validation data came from clinical sites distinct from algorithm-development sites, with no training/test overlap stated in this packet; K243705 itself discloses no sample size or numeric sensitivity, specificity, AUC, or other clinical performance values.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: software unit, integration, and system verification plus retrospective validation described as performed under prior submission K222275. Validation data came from clinical sites distinct from algorithm-development sites, with no training/test overlap stated in this packet; K243705 itself discloses no sample size or numeric sensitivity, specificity, AUC, or other clinical performance values.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Saige-Density (2.5.0) regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K243705
IndependenceIndependence not established
K243705
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K243705. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: A single x-ray mammogram study with acceptable 2D image DICOM files from FFDM and/or 2D synthetic images, used with compatible FFDM and DBT systems; labeled patients are females aged 35 or older undergoing mammography.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM SR and DICOM Secondary Capture outputs are viewable on a mammography workstation. The submission describes single-execution and cloud-enabled deployment options, but the exact commercial deployment topology and local PACS/RIS/EHR interface are not established in the packet.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the subject device as including a new single-execution deployment option and added consideration of deployment in a cloud-enabled environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Compared to the predicate device, the subject device includes a new deployment option (single-execution mode), added consideration of deployment in a cloud-enabled environment, as well as upgrades to improve speed and memory use.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: One study-level breast-density category from A through D under BI-RADS 5th Edition guidelines, delivered as a DICOM Structured Report containing the case-level category and a DICOM Secondary Capture summary report viewable on a mammography workstation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: One study-level breast-density category from A through D under BI-RADS 5th Edition guidelines, delivered as a DICOM Structured Report containing the case-level category and a DICOM Secondary Capture summary report viewable on a mammography workstation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the subject device as including a new single-execution deployment option and added consideration of deployment in a cloud-enabled environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Compared to the predicate device, the subject device includes a new deployment option (single-execution mode), added consideration of deployment in a cloud-enabled environment, as well as upgrades to improve speed and memory use.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
DICOM SR and DICOM Secondary Capture outputs are viewable on a mammography workstation. The submission describes single-execution and cloud-enabled deployment options, but the exact commercial deployment topology and local PACS/RIS/EHR interface are not established in the packet.
ACR AI Central provides an exact-submission model card for Saige-Density (2.5.0); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K243705 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.